FDA Grants Accelerated Approval to Encorafenib with Cetuximab and mFOLFOX6 for Patients with BRAF V600E-mutated mCRC By Ogkologos - January 24, 2025 717 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the BREAKWATER study Source RELATED ARTICLESMORE FROM AUTHOR New Targeted Therapy Shows Promising Early Results in Advanced Pancreatic Cancer FDA Approves Pivekimab Sunirine-pvzy for Blastic Plasmacytoid Dendritic Cell Neoplasm, an Ultra-Rare Haematologic Malignancy Ivonescimab Plus Chemotherapy Improves OS Compared with Tislelizumab Plus Chemotherapy in Previously Untreated Patients with Advanced Squamous NSCLC MOST POPULAR Implementation of Door-to-Door HPV-based Cervix Screening Results in Better Attendance of... April 17, 2023 Primary Tumour Resection Does Not Prolong OS in Patients with Treatment-Naïve... March 7, 2024 Biomedical Engineering Student Invents Device for At-Home Breast Cancer Screening January 6, 2021 Five Questions With…Fern, Christina, Mary, and Shelley. May 26, 2022 Load more HOT NEWS Coffee Shop Owner Learns He Has Terminal Cancer – So Competitor... Mom Diagnosed With Breast Cancer Adopts Healthy Lifestyle To Reinvent Her... 2020 Cancer Incidence and Mortality in EU-27 Countries Our COVID-19 Response: How GreaterGood Is Making An Impact During The...
